Search This Blog

Thursday, December 21, 2023

SCOTUS Should Rule Unanimously Against Trump Ballot Ban

 by Jonathan Turley,

In his book Profiles of Courage, John F. Kennedy discussed figures who answered the call of history and how such defining moments are “an opportunity that sooner or later is presented to us all.” That moment will now be presented to nine justices of the United States Supreme Court after a divided decision of the Colorado Supreme Court to disqualify Donald Trump in the 2024 election.

The test for the U.S. Supreme Court is not just what they should do, but how they should do it.

As an institution, the Court is often called upon to seize such moments to bring unity and clarity on our core values. That is why this insidious opinion must not only be unequivocal but unanimous.

The Colorado decision to bar Donald Trump from the ballot will be overturned because it is wrong on the history and the language of the 14th Amendment.

Dead wrong.

The question is whether the US Supreme Court will speak with one voice, including the three liberal justices.

As with the three Democratic state justices who refused to sign off on the Colorado opinion, these federal justices can now bring a moment of unity not just for the court but the country in rejecting this shockingly anti-democratic theory.

For years, the disqualification theory has been treated like some abstract parlor game for law professors.

While Democrats called for the disqualification of 120 House members, it was treated as a fringe theory.

It has now lost its charm as a legal brain teaser.

As I have previously written, the disqualification of Trump is based on the use of a long-dormant provision in Section 3 of the 14th Amendment.

After the Civil War, House members were outraged to see Alexander Stephens, the Confederate vice president, seeking to take the oath with an array of other former Confederate senators and military officers.

They had all previously taken the same oath and then violated it to join a secession movement that claimed the lives of hundreds of thousands of Americans.

That was a true rebellion.

January 6, 2021, was a riot.

That does not excuse those who committed crimes that day — but it was not an insurrection.

The majority on the Colorado Supreme Court adopted sweeping interpretations of every element of the decision to find that Trump not only incited an insurrection, but can be disqualified under this provision.

It does not matter that Trump has never been charged with even incitement or that he called for his supporters to go to the Capitol to protest “peacefully.”

In finding that Trump led an actual insurrection, the four justices used speeches going back to 2016 to show an effort to rebel before Trump was ever president.

There are ample grounds to summarily toss this opinion to the side.

However, that would not answer the call of this historic moment.

What these four justices did was a direct assault on our democratic process in seeking to bar the most popular candidate in the upcoming election.

Whatever the view of Trump, this is a decision that should rest with the voters.

No only are these four justices seeking to bar the votes of millions of voters (even barring the counting of write-in votes), but they are doing so in the name of democracy.

It is the ballot cleansing that is usually associated with authoritarian countries like Iran, where voters are protected from “unworthy” candidates.

Justice Robert Jackson once observed that he and his colleagues “are not final because we are infallible, we are infallible because we are final.”

A decision on Colorado could put this theory to rest by the sheer finality of the appeal.

However, it is not the finality that is needed at this moment. We need clarity. Clarity of purpose and principle.

The Supreme Court plays a unique role in our system at times like these.

It must at times defy us in rejecting racism as cases such as Brown v. Board of Education.

At other times, it has protected in rejecting government overreach as in cases such as Katz v. United States, demanding warrants to overcome the reasonable expectation of privacy.

This is a time where it can unify us.

The court holds the ultimate “bully pulpit” that can educate citizens on what defines us as a people.

Most people understand intuitively that what these four justices did in Colorado was wrong.

However, the court can speak as one — conservatives and liberals — in reaffirming the core values discarded by these state justices.

In that sense, it may be the greatest test of Chief Justice John Roberts.

Roberts once observed that “the most successful chief justices help their colleagues speak with one voice.”

Past chief justices from John Marshall to Earl Warren struggled to secure unanimous votes on fundamental cases to reaffirm such defining values.

The court could help unify this country in a way that may be unparalleled in its history.

It can show that justices who hold vastly different ideological views can be unified on core principles.

It can remind us that, as citizens, the Constitution is ultimately not a covenant with the government but with each other.

It is a leap of faith that, as a free people, we can decide our shared destiny and protect our shared identity.

The moment has come for nine justices to speak in one voice.

An American voice that transcends the personalities and divisions of our time.

It is a voice that speaks not to what divides us but what defines us as a people.

https://www.zerohedge.com/political/turley-scotus-should-rule-unanimously-against-trump-ballot-ban

Sellas: Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

 - SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% -

- One Patient with Complete Metabolic Response Continuing Treatment for over 62 weeks and another patient with Complete Response by CT Continuing Treatment for over 24 weeks -

- Phase 1b/2 Study in PTCL Ongoing with top line data expected in 1H 2024 -

https://www.biospace.com/article/releases/sellas-receives-fda-orphan-drug-designation-for-sls009-for-treatment-of-peripheral-t-cell-lymphomas/

Clene: initial findings from the Phase 2 ALS programs insufficient to support accelerated approval

 Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today provided an ALS regulatory update from its recent meeting with the U.S. Food and Drug Administration (FDA).

Clene met with the FDA to discuss CNM-Au8® for the treatment of ALS, presenting initial clinical and Neurofilament Light Chain (NfL) biomarker results from the completed Phase 2 ALS studies. Clene also presented the evidence of long-term survival data from these studies as well as the supportive safety data of more than 500 years of participant exposure to date without any identified safety signals across ALS, MS, and Parkinson’s disease.

The FDA determined that the initial findings on biomarker NfL reduction from the Phase 2 programs were insufficient to support accelerated approval at this time. Clene is looking forward to providing supplemental data for further engagement with the FDA in the first half of 2024, including additional long-term clinical evidence and biomarker results of CNM-Au8’s treatment benefit in people living with ALS. Clene plans to demonstrate how CNM-Au8’s mechanism of action is linked to the reduction in NfL, and the association between observed NfL reductions and improved clinical outcomes in ALS patients, including increased survival time.

https://www.globenewswire.com/news-release/2023/12/21/2799889/0/en/Clene-Provides-Update-on-ALS-Clinical-Development-Meeting-With-FDA.html

Hookipa: $21.25 Million Equity Investment from Gilead

 

  • Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share

  • Following the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock

  • Equity investment is to advance the Gilead-partnered HIV therapeutic program through Phase 1; trial expected to commence in the first half of 2024

Oil Tumbles After Angola Announces It Is Leaving OPEC

 Confirming a move which had been widely expected after the internal acrimony at the last OPEC+ meeting, moments ago Angola - also known as China's gas station in Africa - announced it was leaving OPEC, the country's news agency ANGOP reported on Thursday, quoting the African producer’s oil minister Diamantino de Azevedo.

The decision was taken at a meeting of the Council of Ministers, led by the President of the Republic, João Lourenço, the news agency noted. Jornal de Angola also reported the news.

As OilPrice notes, Angola and another African OPEC member, Nigeria, had a spat with the other cartel members before the latest meeting regarding their oil production quotas.

At a meeting in June, Angola and Nigeria were given lower crude oil production quotas as part of the OPEC+ agreement, after the two producers had underperformed and failed to pump to their quotas for years, due to a lack of investment in new fields and maturing older oilfields.

The most recent spat within OPEC about the African countries’ quotas was one of the reasons for the cartel to postpone its latest meeting within a few days.

African OPEC members Angola, Congo, and Nigeria were forced to commit to lower output in 2024, and the originally scheduled November 26 meeting could potentially have pressured them to make further production cuts, as the Saudis expressed discontent over compliance with the deal as it shoulders the bulk of the burden. 

Before the meeting at the end of November, Angola said it was not considering quitting the cartel.

“There’s no thinking in that direction,” Angola OPEC governor Estevao Pedro told Bloomberg at the time, assuring markets that Africa’s second-largest producer had no intentions of rocking the boat to that extent.

However, it seems now that Angola doesn’t see an OPEC membership as beneficial anymore after the recent spats over its production quota.  

Angola, which joined OPEC in 2007, holds untapped oil and gas resources estimated at 9 billion barrels of proven crude oil reserves and 11 trillion cubic feet of proven natural gas reserves.  

The news sent oil, which had caught a bid in recent days on fears about a protracted Red Sea blockage, sharply lower and back to Tuesday levels.

https://www.zerohedge.com/commodities/oil-tumbles-after-angola-announces-it-leaving-opec

BioNTech, Duality: Breakthrough Therapy Designation for Antibody-Drug Conjugate in Endometrial Cancer

 

  • Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of anti-tumor activity
  • Breakthrough Therapy designation will allow for an expedited development and regulatory review of BNT323/DB-1303
  • Endometrial or uterine cancer is the second most common gynecologic cancer globally with over 400,000 cases occurring each year

Sanofi: collaboration agreement extended with Exscientia

 British start-up Exscientia announced on Thursday an extension of its strategic collaboration agreement with Sanofi, which will be strengthened by a new program.



The artificial intelligence (AI)-based pharmaceutical technology company says it has identified a new target showing a promising degree of efficacy based on the preliminary data it has been able to gather.

The two companies signed a research agreement last year to develop up to 15 new small molecule candidates in oncology and immunology, using Exscientia's AI platform.

This personalized medicine technology enables the integration of primary human tissue samples into the drug discovery process.

Under the terms of the new agreement, Exscientia will receive an upfront payment of $45 million from Sanofi, to which could be added payments and royalties of over $300 million.

The upfront cash payment of $45 million is expected to be reflected in Exscientia's first-quarter 2024 financial results, whose shares were expected to rise by 8% on Thursday on the Nasdaq.